BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 24793843)

  • 1. Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease.
    Wolf MB; Murray F; Kilk K; Hillengass J; Delorme S; Heiss C; Neben K; Goldschmidt H; Kauczor HU; Weber MA
    Eur J Radiol; 2014 Jul; 83(7):1222-1230. PubMed ID: 24793843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective comparison of conventional radiography, low-dose computed tomography and magnetic resonance imaging in monoclonal gammopathies.
    Minarik J; Krhovska P; Hrbek J; Pika T; Bacovsky J; Herman M; Scudla V
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Jun; 160(2):305-9. PubMed ID: 26740048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system.
    Schmidt GP; Baur-Melnyk A; Herzog P; Schmid R; Tiling R; Schmidt M; Reiser MF; Schoenberg SO
    Invest Radiol; 2005 Dec; 40(12):743-53. PubMed ID: 16304476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interobserver agreement of whole-body magnetic resonance imaging is superior to whole-body computed tomography for assessing disease burden in patients with multiple myeloma.
    Lai AYT; Riddell A; Barwick T; Boyd K; Rockall A; Kaiser M; Koh DM; Saffar H; Yusuf S; Messiou C
    Eur Radiol; 2020 Jan; 30(1):320-327. PubMed ID: 31267214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging.
    Bäuerle T; Hillengass J; Fechtner K; Zechmann CM; Grenacher L; Moehler TM; Christiane H; Wagner-Gund B; Neben K; Kauczor HU; Goldschmidt H; Delorme S
    Radiology; 2009 Aug; 252(2):477-85. PubMed ID: 19703885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
    Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
    Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma.
    Dutoit JC; Vanderkerken MA; Verstraete KL
    Eur J Radiol; 2013 Sep; 82(9):1444-52. PubMed ID: 23726124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Staging of colon cancer: whole-body MRI vs. whole-body PET-CT--initial clinical experience.
    Squillaci E; Manenti G; Mancino S; Cicciò C; Calabria F; Danieli R; Schillaci O; Simonetti G
    Abdom Imaging; 2008; 33(6):676-88. PubMed ID: 18373114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography.
    Horger M; Claussen CD; Bross-Bach U; Vonthein R; Trabold T; Heuschmid M; Pfannenberg C
    Eur J Radiol; 2005 May; 54(2):289-97. PubMed ID: 15837412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT.
    Herrmann K; Queiroz M; Huellner MW; de Galiza Barbosa F; Buck A; Schaefer N; Stolzman P; Veit-Haibach P
    BMC Cancer; 2015 Dec; 15():1002. PubMed ID: 26699124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body MRI and PET/CT in multiple myeloma patients during staging and after treatment: personal experience in a longitudinal study.
    Cascini GL; Falcone C; Console D; Restuccia A; Rossi M; Parlati A; Tamburrini O
    Radiol Med; 2013 Sep; 118(6):930-48. PubMed ID: 23801394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the utility of whole-body MRI with and without contrast-enhanced Quick 3D and double RF fat suppression techniques, conventional whole-body MRI, PET/CT and conventional examination for assessment of recurrence in NSCLC patients.
    Ohno Y; Nishio M; Koyama H; Yoshikawa T; Matsumoto S; Takenaka D; Seki S; Tsubakimoto M; Sugimura K
    Eur J Radiol; 2013 Nov; 82(11):2018-27. PubMed ID: 24012452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic accuracy of whole-body diffusion-weighted magnetic resonance imaging with 3.0 T in detection of primary and metastatic neoplasms.
    Akay S; Kocaoglu M; Emer O; Battal B; Arslan N
    J Med Imaging Radiat Oncol; 2013 Jun; 57(3):274-82. PubMed ID: 23721135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT.
    Schmidt GP; Baur-Melnyk A; Haug A; Heinemann V; Bauerfeind I; Reiser MF; Schoenberg SO
    Eur J Radiol; 2008 Jan; 65(1):47-58. PubMed ID: 18082989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of whole-body MRI to detect the recurrence of lung cancer.
    Lee MH; Kim SR; Park SY; Park SJ; Lee EJ; Jin GY; Lee YC
    Magn Reson Imaging; 2012 Dec; 30(10):1439-45. PubMed ID: 22817957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)?
    Spira D; Weisel K; Brodoefel H; Schulze M; Kaufmann S; Horger M
    Acad Radiol; 2012 Jan; 19(1):89-94. PubMed ID: 22142681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnostic value of whole-body MRI and bone scintigraphy in the detection of osseous metastases in patients with breast cancer--A Prospective Double-Blinded Study at two Hospital Centers].
    Ohlmann-Knafo S; Kirschbaum M; Fenzl G; Pickuth D
    Rofo; 2009 Mar; 181(3):255-63. PubMed ID: 19229791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
    Schmidt GP; Kramer H; Reiser MF; Glaser C
    Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
    Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
    Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of qualitative and quantitative CT and MRI parameters for monitoring of longitudinal spine involvement in patients with multiple myeloma.
    Horger M; Fritz J; Thaiss WM; Ditt H; Weisel K; Haap M; Kloth C
    Skeletal Radiol; 2018 Mar; 47(3):351-361. PubMed ID: 29222688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.